Literature DB >> 15913464

What is ventilator-associated pneumonia and why is it important?

Marin H Kollef1.   

Abstract

Hospital-associated pneumonia (HAP) is one of the most common infections acquired among hospitalized patients. HAP is associated with excess mortality and increased medical care costs. The rise in HAP due to antibiotic-resistant bacteria has resulted in more common administration of inappropriate antimicrobial treatment, with an associated increased risk of hospital mortality. Ventilator-associated pneumonia (VAP) refers to HAP occurring in patients requiring mechanical ventilation. VAP is the most common nosocomial infection among patients with acute respiratory failure. Physicians treating patients with HAP and VAP should be aware of the predominant local pathogens associated with these infections and their antimicrobial susceptibility patterns. This will allow more appropriate initial antibiotic selection in order to optimize treatment regimens and clinical outcomes. Additionally, clinical strategies aimed at the prevention of HAP and VAP should be employed in all hospital settings caring for patients at risk for these infections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15913464

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  46 in total

1.  Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline.

Authors:  Sujata M Bhavnani; Christopher M Rubino; Jeffrey P Hammel; Alan Forrest; Nathalie Dartois; C Angel Cooper; Joan Korth-Bradley; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  Prophylactic sequential bronchoscopy after inhalation injury: results from a three-year prospective randomized trial.

Authors:  J A Carr; N Crowley
Journal:  Eur J Trauma Emerg Surg       Date:  2013-01-22       Impact factor: 3.693

3.  Ventilator-associated pneumonia: diagnosis, treatment, and prevention.

Authors:  Steven M Koenig; Jonathon D Truwit
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

4.  Ventilatory weaning practices in intensive care units in the city of Cali.

Authors:  Vilma Muñoz; Lucía Calvo; María Fernanda Ramírez; Marcela Arias; Mario Villota; Esther Cecilia Wilches-Luna; Rodolfo Soto
Journal:  Rev Bras Ter Intensiva       Date:  2014 Apr-Jun

5.  Amikacin-fosfomycin at a five-to-two ratio: characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibiotics.

Authors:  A Bruce Montgomery; Paul R Rhomberg; Tammy Abuan; Kathie-Anne Walters; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

6.  Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial.

Authors:  Lee E Morrow; Marin H Kollef; Thomas B Casale
Journal:  Am J Respir Crit Care Med       Date:  2010-06-03       Impact factor: 21.405

Review 7.  Bugs or drugs: are probiotics safe for use in the critically ill?

Authors:  Lindsay M Urben; Jennifer Wiedmar; Erica Boettcher; Rodrigo Cavallazzi; Robert G Martindale; Stephen A McClave
Journal:  Curr Gastroenterol Rep       Date:  2014

8.  Rapid automated microscopy for microbiological surveillance of ventilator-associated pneumonia.

Authors:  Ivor S Douglas; Connie S Price; Katherine H Overdier; Robert F Wolken; Steven W Metzger; Kenneth R Hance; David C Howson
Journal:  Am J Respir Crit Care Med       Date:  2015-03-01       Impact factor: 21.405

9.  Incidence and risk factors of ventilator associated pneumonia in a tertiary care hospital.

Authors:  Mv Pravin Charles; Joshy M Easow; Noyal M Joseph; M Ravishankar; Shailesh Kumar; Sivaraman Umadevi
Journal:  Australas Med J       Date:  2013-04-30

10.  Decrease of CD4-lymphocytes and apoptosis of CD14-monocytes are characteristic alterations in sepsis caused by ventilator-associated pneumonia: results from an observational study.

Authors:  Aimilia Pelekanou; Iraklis Tsangaris; Antigoni Kotsaki; Vassiliki Karagianni; Helen Giamarellou; Apostolos Armaganidis; Evangelos J Giamarellos-Bourboulis
Journal:  Crit Care       Date:  2009-11-02       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.